Veru Inc. (VERU)

Latest News

View All News

November 5, 2024 • 8:30AM EST

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Read Press Release

October 21, 2024 • 8:30AM EDT

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

October 16, 2024 • 8:30AM EDT

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

September 11, 2024 • 8:30AM EDT

Veru to Present at the 2024 Cantor Global Healthcare Conference

View All News

Latest Presentation

2024 Cantor Global Healthcare Conference, September 2024

View Presentation View All Presentations

Recent Event

November 5, 2024 2:30 pm CST – 3:30 pm CST

ObesityWeek

View All Events

Latest Financial Results

Q3 2024

Quarter Ended June 30, 2024

Earnings Release

PDF HTML

Earnings Webcast

Audio

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending September 30, 2023

Analyst Coverage

Firm	Analyst
Jefferies	Dennis Ding
Oppenheimer	Leland Gershell
H.C. Wainwright	Yi Chen
Raymond James	Gary Nachman
B. Riley	William Wood

Contacts

Company

Veru Inc.
2916 N. Miami Avenue
Suite 1000
Miami, FL 33127
United States
T: 305-509-6897
veruinvestor@verupharma.com

Investor Relations

Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Veruinvestor@verupharma.com

Media

media@verupharma.com